Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-08-30
2011-08-30
Ha, Julie (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S001200, C514S007200, C530S300000, C530S308000, C530S324000
Reexamination Certificate
active
08008255
ABSTRACT:
Provided are methods and compositions for enhancing the transmucosal absorption of bioactive peptides and proteins. More particularly, the invention provides compositions for enhancing the transmucosal absorption of bioactive peptides and proteins, such as exendin-4, PYY, PYY3-36, and GLP-1 and their analogs and derivatives, wherein the compositions comprise an absorption enhancing mixture of a cationic polyamino acid and a buffer that is compatible with the polyamino acid. Also provided are methods for enhancing the transmucosal absorption and bioavailability of bioactive peptides and proteins using such compositions.
REFERENCES:
patent: 4476116 (1984-10-01), Shabbir
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5116817 (1992-05-01), Shabbir
patent: 5124314 (1992-06-01), Cooper
patent: 5330761 (1994-07-01), Baichwal
patent: 5367052 (1994-11-01), Cooper et al.
patent: 5424286 (1995-06-01), Eng
patent: 5512549 (1996-04-01), Chen
patent: 5554388 (1996-09-01), Illum
patent: 5574008 (1996-11-01), Johnson et al.
patent: 5580953 (1996-12-01), Albrecht et al.
patent: 5686411 (1997-11-01), Gaeta et al.
patent: 5705483 (1998-01-01), Galloway et al.
patent: 5788959 (1998-08-01), Singh
patent: 5804212 (1998-09-01), Illum
patent: 5846937 (1998-12-01), Drucker
patent: 5977070 (1999-11-01), Piazza et al.
patent: 5981488 (1999-11-01), Hoffmann
patent: 6294153 (2001-09-01), Modi
patent: 6346274 (2002-02-01), Koll et al.
patent: 6391318 (2002-05-01), Illum et al.
patent: 6440392 (2002-08-01), Stern
patent: 6528486 (2003-03-01), Larsen et al.
patent: 6610824 (2003-08-01), Gaeta et al.
patent: 6703359 (2004-03-01), Young et al.
patent: 6767887 (2004-07-01), Hoffmann et al.
patent: 2002/0009491 (2002-01-01), Rothbard et al.
patent: 2002/0137666 (2002-09-01), Beeley et al.
patent: 2002/0141985 (2002-10-01), Pittner et al.
patent: 2003/0087820 (2003-05-01), Young et al.
patent: 2003/0087821 (2003-05-01), Beeley et al.
patent: 2003/0220243 (2003-11-01), Glaesner et al.
patent: 2004/0053819 (2004-03-01), Dodd et al.
patent: 2005/0215475 (2005-09-01), Ong et al.
patent: 19921537 (2000-11-01), None
patent: 1998095738 (1998-04-01), None
patent: 2000281589 (2000-10-01), None
patent: WO 99/07404 (1999-02-01), None
patent: WO 9907404 (1999-02-01), None
patent: WO 99/25727 (1999-05-01), None
patent: WO 99/25728 (1999-05-01), None
patent: WO 9940788 (1999-08-01), None
patent: WO 00/41546 (2000-07-01), None
patent: WO 00/66629 (2000-11-01), None
patent: WO 01/04156 (2001-01-01), None
patent: WO 01/98331 (2001-12-01), None
patent: WO 02/47712 (2002-06-01), None
patent: WO 02/48192 (2002-06-01), None
patent: WO02/098348 (2002-12-01), None
patent: WO 03/026591 (2003-04-01), None
NPL-PYY sequence from NCBI GenBank Accession No. P68005. Accessed Apr. 23, 2008.
Walker, et al. , Pharmaceutical Research, 1999, vol. 16, pp. 1074-1080.
Callens, C., et al, “Evaluation of Starch-Maltodextrin-Carbopol 974 Mixtures for the Nasal Delivery of Insulin in Rabbits”, J. Control Release, 2000, pp. 215-220, vol. 66(2-3).
Dyer, A.M., et al, “Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study . . . ”, Pharm Res., 2002, pp. 998-1008, vol. 19(7).
Fernandez-Urrusuno, R., et al, “Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles”, Pharm Res., Oct. 1999, pp. 1576-1581, vol. 16(10).
Illum, L., et al, “Chitosan as a Novel Nasal Delivery System for Peptide Drugs”, Pharm Res., Aug. 1994, pp. 1186-1189, vol. 11(8).
Kyte, J., et al, “A Simple Method for Displaying the Hydropathic Character of a Protein”, J Mol Biol., May 1982, pp. 105-132, vol. 157(1).
McEwan, G.T., et al, “Polycation-Induced Enhancement of Epithelial Paracellular Permeability . . . ”, Biochem Biophys Acta., May 14, 1993, pp. 51-60, vol. 1148(1).
Miyamoto, M., et al, “Improved Nasal Absorption of Drugs Using Poly-L-Arginine: Effects of Concentration . . . ”, Eur J Pharm Biopharm, Jul. 2001, pp. 21-30, vol. 52(1).
Miyamoto, M., et al, “Effect of Poly-L-Arginine on the Nasal Absorption . . . ”, Int J Pharm., Sep. 11, 2001, pp. 127-138, vol. 226(1-2).
Natsume, H., et al, “Screening of Cationic Compound as an Absorption Enhancer . . . ”, Int J Pharm., Aug. 5, 1999, pp. 1-12, vol. 185(1).
Ohtake, K., et al, “Analysis of Transient and Reversible Effects of Poly-L-Arginine on the In Vivo Nasal . . . ”, J Control Release, Aug. 21, 2002, pp. 263-275, vol. 82(2-3).
Ohtake, K., et al, “Poly-L-Arginine Enhances Paracellular Permeability Via Serine/Threonine Phosphorylation . . . ” Pharm Res., Nov. 2003, pp. 1838-1845, vol. 20(11).
Uchida, D.A., et al, “Cationic Proteins Increase the Permeability of Cultured Rabbit Tracheal Epithelial . . . ” Exp Lung Res., Jan. 1996-Feb. 1996, pp. 85-99, vol. 22(1).
Jennings Robert
Ong John
Stetsko Gregg
Amylin Pharmaceuticals Inc.
Ha Julie
LandOfFree
Methods and compositions for enhanced transmucosal delivery... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for enhanced transmucosal delivery..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for enhanced transmucosal delivery... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2700294